Enterprise Financial Services Corp Bei Gene, Ltd. Transaction History

Enterprise Financial Services Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$249.6 - $403.14 $9,734 - $15,722	-39 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$221.31 - $316.61 $663 - $949	3 Added 8.33%	39 $10,000
Q2 2020 Aug 04, 2020	SELL	$123.9 - $195.41 $619 - $977	-5 Reduced 12.2%	36 $7,000
Q1 2020 May 15, 2020	BUY	$121.84 - $173.19 $3,411 - $4,849	28 Added 215.38%	41 $5,000
Q4 2019 Jan 28, 2020	BUY	$115.78 - $208.34 $694 - $1,250	6 Added 85.71%	13 $2,000
Q1 2019 Apr 26, 2019	BUY	$122.82 - $151.83 $859 - $1,062	7 New	7 $1,000

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.3B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Enterprise Financial Services Corp, based on Form 13F filings with the SEC.

Stay updated on Enterprise Financial Services Corp with notifications on news.